Relmada reports positive preclinical psilocybin data for MASLD; Phase 1 in early 2024

RELMADA THERAPEUTICS, INC.

Low-dose psilocybin (0.05 mg/kg, daily oral) in HFHFD mice reduced liver steatosis, body weight (12% reduction), and fasting blood glucose (p<0.05).
Mechanism involves 5-HT-2A receptor agonism, distinct from GLP-1 agents; restored plasma/liver triglyceride levels to normal-diet levels.
Company to initiate single-ascending dose Phase 1 trial in obese MASLD patients in early 2024.
Data to be presented at AASLD The Liver Meeting 2023 (Nov 10-14, 2023, Boston).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.